Vision & Mission
Our Vision: Focus on the needs of patients to achieve the goals of effective treatment of diseases and reasonable medical expenses through our "innovative immune cell therapy". To make cellular gene therapy faster, cheaper, and better and to make them affordable and accessible to patients.
Our Mission: Transform the lives of patients with unmet medical needs through pursuing science in action, conquering adversity with resilience, teamwork in collaboration, and a commitment to excellence.
ARCE is developing best-in-class CAR-T cell therapy products via three technology platforms, DashCARTM, MaxCARTM, and OneCARTM, for the treatment of various forms of cancer, including hematological cancers and solid tumors, in human patients and potentially in canine oncology. As CAR-T therapy gains momentum in treating cancers, we bear a sense of a time-bound mission to guard its safety, while exploring its unlimited potential in curing a wide spectrum of diseases.
ARCE is to Accelerate the Revolution in Cell Engineering
Striving for innovations of cancer therapeutics in Action, Resilience, Collaboration, and Excellence!
Take action and responsibility in combating cancer with novel immunotherapies, such as CAR-T treatments, to transform patients’ lives.
Harness patients’ own immune system against malignancies and to grant patients with resilience in fending off life-threatening diseases.
We collaborate with partners globally on merging various expertise and platforms to create one-of-a-kind cell therapies that will turn the tide against cancer.
ARCE aims to generate best-in-class cell therapies with excellent safety, potency and durability profiles which will benefit more patients.
CHALLNGES IN CANCER IMMUNOTHERAPY
The field of immuno-oncology is booming. The ability to rewire our own immune system for fighting cancer has forever changed the medical landscape. CAR-T therapy involves genetic modifications of patient’s T cells, followed by ex vivo cell expansion and re-infusion back to the patient. To date, clinical results of CD19 CAR-T therapy in end-stage ALL and lymphoma patients were promising and have received FDA-approvals.
Despite the successful results of CAR-T therapy in hematological cancers, there are three major challenges remained to be addressed as follows:
(1) To decrease the toxicities, such as the life-threatening cytokine release syndrome (CRS), a side effect that comes with CAR-T administration.
(2) To tackle solid tumors, which comprise 95% of all cancers, by finding suitable targets, and to adapt novel CAR designs to overcome the immune-suppressive tumor microenvironment.
(3) To figure out ways to generate T cells at a lower cost by inventions of a biological and/or technological nature.
STRATEGIES AND GOALS OF ARCE THERAPEUTICS
ARCE is developing CAR-T cell therapies for various forms of cancer, including hematological cancers and solid tumors. Leveraging our R&D vitality and cooperation with global partners, we aim to generate state-of-the-art CAR-T therapies with reassuring safety profiles, significant potency and durability. In addition, to develop proprietary technology for fast manufacturing of CAR-T products.
While engaging in new drug development focusing on R&D of preclinical and phase I/II stages, the company executes strategic plan to carry out the following:
(1) Out-licensing patents or model systems (2) Collaborating with large pharmaceutical companies to co-develop novel pipelines. (3) Out-licensing to or partnering with other companies on new pipelines. (4) M&A or IPO as an exit plan.